Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03437473 · ClinicalTrials.gov registry record · NA

Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)

A NA study of Rheumatoid Arthritis, sponsored by SetPoint Medical Corporation.

Completed
Registry status
NA
Development phase
14
Enrollment target
4
Study locations

NCT03437473: Completed NA study of Rheumatoid Arthritis, sponsored by SetPoint Medical Corporation.

NCT03437473 is a NA study of Rheumatoid Arthritis that has completed, run by SetPoint Medical Corporation. The registered enrollment target is 14 participants, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03437473, a NA study of Rheumatoid Arthritis, has completed, sponsored by SetPoint Medical Corporation.

COMPLETED
Registry status
NA
Development phase
14 participants
Enrollment target
4
Study locations

Study Summary

Multi-site, first-in-human study to assess safety and efficacy of an active implantable Vagus Nerve Stimulation (VNS) device in 15 adult patients with active moderate-to-severe rheumatoid arthritis who have had an incomplete response or intolerability to at least two different mechanisms of action.

Primary Outcome

treatment-emergent incidence rates of Adverse Events, Adverse Device Effects, Serious Adverse Events, Serious Adverse Device Effects, Unanticipated Adverse Device Effects, and Unanticipated Serious Adverse Device Effects

Conditions Studied

Interventions

  • DEVICE SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System

Study Locations (4)

Florida

  • Arthritis & Rheumatic Disease Specialties - Aventura
  • Florida Medical Clinic, P.A. - Zephyrhills

New York

  • Northwell Health Division of Rheumatology - Great Neck

Pennsylvania

  • Altoona Center for Clinical Research - Duncansville

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2018-03-06
Est. Completion 2018-12-10
Phase NA
SetPoint Medical Corporation

4 total trials

What the finished NCT03437473 record still lists

NCT03437473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System is the first listed.

NCT03437473 reports a single indexed study location in Florida, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03437473 about?

NCT03437473 is a clinical study titled "Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)". Multi-site, first-in-human study to assess safety and efficacy of an active implantable Vagus Nerve Stimulation (VNS) device in 15 adult patients with active moderate-to-severe rheumatoid arthritis who have had an incomplete response or intolerability to at least two different mechanisms of action.

What is the current status of trial NCT03437473?

This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2018-03-06. Estimated completion is 2018-12-10.

What conditions does trial NCT03437473 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT03437473?

The interventions under investigation include: SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System (DEVICE).

Who is sponsoring clinical trial NCT03437473?

This trial is sponsored by SetPoint Medical Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03437473 being conducted?

This trial has 4 study locations across Florida, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03437473's enrollment target sits among peer trials

14 190th of 197 higher than 5 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT03437473, the US trial registry maintained by the National Library of Medicine. NCT03437473 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.